RecruitingNCT05477979

The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)

Cohort Studies of Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging (STRESS-LUNG)

Sponsor

Second Xiangya Hospital of Central South University

Enrollment

750 participants

Start Date

Jun 1, 2020

Study Type

OBSERVATIONAL

Conditions

Lung Cancer Cancer, Treatment-Related Psychological Stress Immune Checkpoint Inhibitors

Summary

This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer. The participants including the patients diagnosed with advanced non-small-cell lung cancer (NSCLC) who received the first-line therapy or neoadjuvant therapy of ICIs; patients diagnosed with advanced small-cell lung cancer (SCLC) receiving the first-line therapy ICIs; patients diagnosed with early small-cell lung cancer (SCLC) receiving surgery.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is exploring whether psychological stress affects how well lung cancer treatments work and impacts overall survival. Researchers want to better understand the link between mental well-being and cancer treatment outcomes to help improve care for lung cancer patients. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced non-small cell lung cancer (NSCLC, Stage IIIB–IV) or small cell lung cancer - You are about to start or are currently receiving immunotherapy (PD-1/PD-L1 inhibitors), with or without chemotherapy - You have not previously received systemic cancer treatments - You are able to participate in psychological assessments **You may NOT be eligible if...** - Your tumor has certain genetic mutations (EGFR, ALK, or ROS1 positive) - You have a current or past psychiatric disorder or are receiving anti-anxiety/anti-depression therapy - You have symptomatic brain metastases - You have had another cancer in the past 3 years Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERExposure: psychological stress status

The assessment of depressive and anxiety symptoms was conducted using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder Assessment 7 (GAD-7). Patients with a PHQ-9 score ≥ 5 or a GAD-7 score ≥ 5 were categorized as the stressed group.